Arcus Biosciences, Inc. (RCUS)
RCUS moved a median of -0.09% 30 minutes after news, and 0.00% by the close. How RCUS actually reacts to news — the realized, point-in-time move the market made, measured across 368 labeled events over the last three years with zero look-ahead.
RCUS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 368 |
| 30-min | -0.09% | 45% | 368 |
| 60-min | +0.12% | 53% | 368 |
| to close | 0.00% | 49% | 366 |
| Middle 50% of RCUS reactions | -0.97% to +1.09% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 368 |
Half of all Arcus Biosciences, Inc. news events land between -0.97% and +1.09% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RCUS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -1.67% | 20% | +1.04% |
| Coverage initiations | 13 | -1.14% | 39% | -2.94% |
| Rating reiterations | 69 | +0.04% | 51% | -0.10% |
| Price-target raises | 12 | +0.40% | 58% | +0.63% |
| Price-target cuts | 14 | +0.76% | 86% | -0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RCUS ranks against every other measured name →
That’s how RCUS usually reacts — get an email when it moves on news →Email me when RCUS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RCUS's baseline. Nothing else.
Recent RCUS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -0.76% | -0.33% | |
| Form CT ORDER Arcus Biosciences, Inc. | SEC filing · Form CT | SEC EDGAR | -0.04% | -1.21% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -0.24% | -0.76% | |
| Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy | Press release | Business Wire | +0.19% | +2.01% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -0.46% | -6.67% | |
| Arcus Biosciences to Participate in Three Upcoming Investor Conferences | Press release | Business Wire | +0.13% | -0.52% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +0.19% | +0.31% | |
| Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update | Press release | Business Wire | -4.32% | -3.64% | |
| Form 10-Q Arcus Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.32% | -3.64% | |
| Form 8-K Arcus Biosciences, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -4.32% | -3.64% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -1.07% | -1.96% | |
| Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer | Press release | Business Wire | +1.42% | -0.90% | |
| Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients | Press release | Business Wire | +1.42% | -0.90% | |
| Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates | Press release | Business Wire | +0.41% | +2.60% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -3.79% | -2.92% | |
| New Research Published in Nature Links Clinical Activity with HIF-2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan | Press release | Business Wire | +0.25% | -3.54% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +1.08% | +5.47% | |
| Form 8-K Arcus Biosciences, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -0.66% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +0.77% | -5.23% | |
| Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD-L1/VEGF-A Bispecific Immunomodulator to Treat Kidney Cancer | Press release | Business Wire | -0.35% | -3.09% | |
| Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +0.13% | +1.05% | |
| Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update | Press release | Business Wire | +0.12% | +3.92% | |
| Form 10-Q Arcus Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.12% | +3.92% | |
| Form 8-K Arcus Biosciences, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +3.92% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +0.75% | -1.85% | |
| Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates | Press release | Business Wire | +0.00% | +6.48% | |
| Form ARS Arcus Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +6.48% | |
| Form DEF 14A Arcus Biosciences, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +6.48% | |
| Form DEFA14A Arcus Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +6.48% | |
| Form 8-K Arcus Biosciences, Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -4.32% | -6.11% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -2.09% | -4.57% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +1.11% | +4.02% | |
| Form 8-K Arcus Biosciences, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +2.89% | +0.66% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +0.67% | +5.95% | |
| Arcus Biosciences to Participate in Two Upcoming Investor Conferences | Press release | Business Wire | +0.74% | +4.46% | |
| Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update | Press release | Business Wire | -2.06% | -1.76% | |
| Form 10-K Arcus Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.06% | -1.76% | |
| Form 8-K Arcus Biosciences, Inc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | -1.76% | |
| Form S-3ASR Arcus Biosciences, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -2.06% | -1.76% | |
| Form S-8 Arcus Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.06% | -1.76% | |
| Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer | Press release | Business Wire | +2.36% | +5.76% | |
| Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates | Press release | Business Wire | -0.05% | -3.58% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | +0.98% | +2.18% | |
| Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs | Press release | Business Wire | +0.90% | -3.57% | |
| Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.36% | +0.00% | |
| Form 8-K Arcus Biosciences, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +0.00% | |
| Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio | Press release | Business Wire | +5.31% | +2.57% | |
| Form 8-K Arcus Biosciences, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +5.31% | +2.57% | |
| Arcus Biosciences Announces New Employment Inducement Grants | Press release | Business Wire | -0.04% | +1.44% | |
| Arcus Biosciences to Participate in Two Upcoming Investor Conferences | Press release | Business Wire | +0.83% | -0.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RCUS section they belong to.
Where else RCUS is measured.
RCUS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
| Microbot Medical Inc. (MBOT) | 366 | -0.19% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arcus Biosciences, Inc.'s median reaction calculated?
Every labeled RCUS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 368 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of RCUS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RCUS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.